A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Elebsiran (Primary) ; Nivolumab (Primary) ; Selgantolimod (Primary) ; Tenofovir alafenamide (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Sponsors Gilead Sciences

22 Oct 2024 According to a Gilead Sciences, Inc. media release, results of this study will be presented at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif.
01 Aug 2024 Status changed from active, no longer recruiting to completed.
21 Dec 2022 Planned End Date changed from 1 Apr 2024 to 1 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com